BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310

Reuters11-21 18:45

Nov 21 (Reuters) - Lipella Pharmaceuticals Inc LIPO.O:

LIPELLA PHARMACEUTICALS ANNOUNCES COMPLETION OF FIRST COHORT IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS, ADVANCING TO NEXT DOSE GROUP
LIPELLA PHARMACEUTICALS INC - TRIAL EXPECTED TO CONCLUDE BY MID-2025 WITH TOP-LINE DATA BY YEAR-END 2024

Source text: ID:nGNX6JCkwl

Further company coverage: LIPO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485446519?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485446519","market":"us","top_or_hot":-1,"title":"BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310</title></head><body><p><span>Nov 21 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/LIPO\">Lipella Pharmaceuticals Inc</a> <span>LIPO.O</span>:</p><ul><li><p>LIPELLA PHARMACEUTICALS ANNOUNCES COMPLETION OF FIRST <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS, ADVANCING TO NEXT DOSE GROUP</p></li><li><p>LIPELLA PHARMACEUTICALS INC - TRIAL EXPECTED TO CONCLUDE BY MID-2025 WITH TOP-LINE DATA BY YEAR-END 2024</p></li></ul><p>Source text: <span>ID:nGNX6JCkwl</span></p><p>Further company coverage: <span>LIPO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 18:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA6Z2TL4:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310Nov 21 (Reuters) - Lipella Pharmaceuticals Inc LIPO.O:LIPELLA PHARMACEUTICALS ANNOUNCES COMPLETION OF ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA6Z2TL4:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LIPO","symbol_name":"Lipella Pharmaceuticals Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA6Z2TL4:1","article_id":"2485446519","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485446519","pubTimestamp":1732185945,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310Nov 21 (Reuters) - Lipella Pharmaceuticals Inc LIPO.O:LIPELLA PHARMACEUTICALS ANNOUNCES COMPLETION OF FIRS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LIPO":"Lipella Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"简介-Lipella Pharmaceuticals宣布完成LP-310 2a期试验的第一个队列","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIPO":0.9},"content_text":"BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310Nov 21 (Reuters) - Lipella Pharmaceuticals Inc LIPO.O:LIPELLA PHARMACEUTICALS ANNOUNCES COMPLETION OF FIRST COHORT IN PHASE 2A TRIAL OF LP-310 FOR ORAL LICHEN PLANUS, ADVANCING TO NEXT DOSE GROUPLIPELLA PHARMACEUTICALS INC - TRIAL EXPECTED TO CONCLUDE BY MID-2025 WITH TOP-LINE DATA BY YEAR-END 2024Source text: ID:nGNX6JCkwlFurther company coverage: LIPO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485446519"}